Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 1/20 | 0.44 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
| ▸ | PPARG | P37231 | 1/20 | 0.41 |
| ▸ | PPARA | Q07869 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | FABP5 | Q01469 | 3/20 | 0.40 |
| ▸ | FABP7 | O15540 | 2/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | CASP3 | P42574 | 1/20 | 0.37 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29779331 | 1.00 | ITGB3 (0.44) | ITGB3ITGA2BEPHX2PPARGPPARA | |
| SCHEMBL28012104 | 0.94 | ITGB3 (0.43) | ITGB3ITGA2BEPHX2PPARGPPARA | |
| SCHEMBL15632804 | 0.94 | ITGB3 (0.43) | ITGB3ITGA2BEPHX2PPARGPPARA | |
| SCHEMBL29633817 | 0.93 | ITGB3 (0.45) | ITGB3ITGA2BEPHX2PPARGPPARA | |
| SCHEMBL29398902 | 0.93 | ITGB3 (0.45) | ITGB3ITGA2BEPHX2PPARGPPARA | |
| SCHEMBL30510296 | 0.93 | ITGB3 (0.45) | ITGB3ITGA2BEPHX2PPARGPPARA | |
| SCHEMBL118926 | 0.93 | ITGB3 (0.45) | ITGB3ITGA2BEPHX2PPARGPPARA | |
| SCHEMBL120595 | 0.93 | ITGB3 (0.45) | ITGB3ITGA2BEPHX2PPARGPPARA | |
| SCHEMBL120592 | 0.93 | ITGB3 (0.45) | ITGB3ITGA2BEPHX2PPARGPPARA | |
| SCHEMBL29400893 | 0.93 | ITGB3 (0.45) | ITGB3ITGA2BEPHX2PPARGPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4339204-A1 | BINDING MOLECULE EXHIBITING SELECTIVE BINDING FOR RAS(G12D) MUTANT | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-03-20 | — | — | EP | disclosed |
| US-11834406-B2 | Conjugates of cell binding molecules with cytotoxic agents | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2023-12-05 | — | — | US | disclosed |
| US-11767294-B2 | Conjugates of cell binding molecules with cytotoxic agents | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2023-09-26 | — | — | US | disclosed |
| US-11612661-B2 | Conotoxin peptide analogs and uses for the treatment of pain and inflammatory conditions | KINETA CHRONIC PAIN, LLC (US) | 2023-03-28 | — | — | US | disclosed |
| US-9493512-B2 | Solution phase processes for the manufacture of macrocyclic depsipeptides and new intermediates | NOVARTIS AG (CH) | 2016-11-15 | — | — | US | disclosed |
| CN-103476789-B | Process for the preparation of macrocyclic depsipeptides and novel intermediates | 诺瓦提斯公司 | 2016-11-09 | — | — | CN | disclosed |
| EP-2906585-A2 | SOLUTION PHASE PROCESSES FOR THE MANUFACTURE OF MACROCYCLIC DEPSIPEPTIDES AND NEW INTERMEDIATES | Novartis AG (CH) | 2015-08-19 | — | — | EP | disclosed |
| US-20150218224-A1 | Solution Phase Processes for the Manufacture of Macrocyclic Depsipeptides and New Intermediates | NOVARTIS AG (CH) | 2015-08-06 | — | — | US | disclosed |
| CN-104804072-A | Processes for the manufacture of macrocyclic depsipeptides and new intermediates | NOVARTIS AG | 2015-07-29 | — | — | CN | disclosed |
| CN-104797592-A | Aldehyde acetal based processes for the manufacture of macrocyclic depsipeptides and new intermediates | NOVARTIS AG | 2015-07-22 | — | — | CN | disclosed |
| US-9067978-B2 | Solution phase processes for the manufacture of macrocyclic depsipeptides and new intermediates | NOVARTIS AG (CH) | 2015-06-30 | — | — | US | disclosed |
| CN-104703997-A | Liquid phase process for the preparation of macrocyclic depsipeptides and novel intermediates | NOVARTIS AG | 2015-06-10 | — | — | CN | disclosed |
| WO-2014057418-A2 | SOLUTION PHASE PROCESSES FOR THE MANUFACTURE OF MACROCYCLIC DEPSIPEPTIDES AND NEW INTERMEDIATES | NOVARTIS AG (CH) | 2014-04-17 | — | — | WO | disclosed |
| US-20140100355-A1 | Solution Phase Processes for the Manufacture of Macrocyclic Depsipeptides and New Intermediates | NOVARTIS AG (CH) | 2014-04-10 | — | — | US | disclosed |
| CN-103476789-A | Process for the preparation of macrocyclic depsipeptides and novel intermediates | NOVARTIS AG | 2013-12-25 | — | — | CN | disclosed |
| US-20070105759-A1 | Melanocortin receptor 4 (mc4) agonists and their uses | ELI LILLY AND COMPANY (US) | 2007-05-10 | — | — | US | disclosed |
| EP-1644023-A2 | MELANOCORTIN RECPTOR 4(MC4) AGONISTS AND THEIR USES | ELI LILLY AND COMPANY (US) | 2006-04-12 | — | — | EP | disclosed |
| WO-2005000339-A2 | MELANOCORTIN RECEPTOR 4(MC4) AGONISTS AND THEIR USES | ELI LILLY AND COMPANY (US) | 2005-01-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11612661-B2 | Conotoxin peptide analogs and uses for the treatment of pain and inflammatory conditions | CHRNG, CHRNA9, CHRNA10 | ITGB3 401/4885ITGA2B 268/4885EPHX2 2218/4885 |
| US-20070105759-A1 | Melanocortin receptor 4 (mc4) agonists and their uses | MC4R, MC3R, MC1R | ITGB3 2629/4885ITGA2B 3754/4885EPHX2 3913/4885 |
| US-11767294-B2 | Conjugates of cell binding molecules with cytotoxic agents | CD4, CD2, CD47 | ITGB3 314/4885ITGA2B 442/4885EPHX2 4253/4885 |
| US-20140100355-A1 | Solution Phase Processes for the Manufacture of Macrocyclic Depsipeptides and New Intermediates | VIP, NPPA, DNPEP | ITGB3 4866/4885ITGA2B 4782/4885EPHX2 1830/4885 |
| US-11834406-B2 | Conjugates of cell binding molecules with cytotoxic agents | CD4, CD2, CD47 | ITGB3 269/4885ITGA2B 426/4885EPHX2 4237/4885 |
| US-20150218224-A1 | Solution Phase Processes for the Manufacture of Macrocyclic Depsipeptides and New Intermediates | VIP, NPPA, DNPEP | ITGB3 4866/4885ITGA2B 4782/4885EPHX2 1830/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.